Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 73

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 73
---
 trading market for these notes (Level 2). The fair value of the Company’s acquisition-related contingent consideration is reported at fair value on a recurring basis (Level 3). The carrying amount of equity investments and convertible notes receivable without readily determinable fair values are recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments.At September 30, 2025, the carrying values and fair values of the following financial assets and liabilities were as follows (in thousands):Carrying ValueFair Value Measurements UsingLevel 1Level 2Level 3Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:Financial Assets:Equity investments$7,750 $— $— $7,750 Convertible notes receivable$2,500 $— $— $2,500 Financial Liabilities:   Acquisition-related contingent consideration$17,834 $— $— $17,834 Financial Liabilities Measured at Amortized Cost:   2.125% convertible senior notes due 2029 (1)$280,721 $— $291,453 $—    Revolving Credit Facility$96,000 $— $96,000 $— (1) The closing price of the Company’s common stock as reported on the Nasdaq Global Select Market was $25.77 per share on September 30, 2025, compared to a conversion price of $39.56 per share. At September 30, 2025, as the conversion price was above the stock price, the requirements for conversion have not been met.

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  22

Financial Assets and Liabilities Measured at Fair Value on a Recurring BasisEquity and Convertible Note InvestmentsThe Company holds strategic investments in clinical and preclinical stage privately-held biotechnology companies in the form of equity and convertible note investments. The following investments have no readily determinable fair value and are recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments (in thousands):Equity InvestmentsConvertible Notes ReceivableTotalBalance at December 31, 2023$15,877 $12,134 $28,011 Foreign currency adjustments— (236)(236)Balance at December 31, 202415,877 11